Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and ...

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...

ARS Pharma will host a webinar for school nurses and administrators about neffy and the neffyinSchools program on January 22, 2025. Participants are encouraged to register here. For more ...

“For ARS Pharma, 2024 marked a pivotal year, securing regulatory approvals for neffy as the first and only intranasal epinephrine treatment, laying a solid foundation for our commercial success ...

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary ...

and CEO of ARS Pharma. “neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis can ...

Presentation at the 43 rd Annual J.P. Morgan Healthcare Conference On Wednesday, January 15, 2025, at 7:30am PT, Richard Lowenthal, President and CEO of ARS Pharma, will present a company overview ...

and CEO of ARS Pharma.“ neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis ...

Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma, will present on Wednesday, January 15, 2025, at 7:30 a.m. PT. Company management will also participate in one-on-one meetings with ...